25-MAY-2024 6:10

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1905-T-ALL/T-LBL, Rel/Ref, OBI-3424 1 Y 1 OBI-3424 8mg 64 5 0 0 0 0 0 02/08/2021 61 25
        2 OBI-3424 10mg   5 0 0 0 0 0      
        3 OBI-3424 12mg   5 2 1 1 1 0      
            15 2 1 1 1 0      
 
  S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O 1 Y 1 Delayed V-O 247 36 12 7 4 1 0 03/02/2021 241 97
        2 Early V-O   67 24 13 6 2 0      
            103 36 20 10 3 0      
 
Yes A041701-AML, Age 60+, Conv Chemo +/- Uproleselan 0 E Total Registrations   52 0 0 0 0 0 06/10/2019 166 58
            52 0 0 0 0 0      
 
    1 E Total Registrations   38 0 0 0 0 0 06/10/2019    
            38 0 0 0 0 0      
 
  A042001-B-Cell ALL, Inotuzunab+chemo v Standard chemo 0 E Total Registrations   2 2 0 0 0 0 10/12/2023 117 44
            2 2 0 0 0 0      
 
    1 E Total Registrations   2 2 0 0 0 0 10/12/2023    
            2 2 0 0 0 0      
 
  EA9152-ALL, T/B-Cell, Venetoclax + Vincristine 0 E Total Registrations   4 3 1 0 0 0 01/17/2023 53 24
            4 3 1 0 0 0      
 
    1 E Total Registrations   3 2 1 0 0 0 01/17/2023    
            3 2 1 0 0 0      
 
  EA9213-T-ALL, dara-hyal for chemo refractory MRD 0 E Total Registrations   5 2 1 0 0 0 02/24/2023 46 16
            5 2 1 0 0 0      
 
    1 E Total Registrations   3 2 1 0 0 0 02/24/2023    
            3 2 1 0 0 0      
 
No A041501-B-Cell ALL, Frontline Tx +/- Intuzumab Ozo 0 E Total Registrations   71 0 0 0 0 0 11/09/2018 222 84
            71 0 0 0 0 0      
 
    1 E Total Registrations   57 0 0 0 0 0 11/09/2018    
            57 0 0 0 0 0      
 
    2 E Total Registrations   44 0 0 0 0 0 11/09/2018    
            44 0 0 0 0 0      
 
  A041703-ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat 0 E Total Registrations   11 1 1 0 0 0 08/13/2020 122 53
            11 1 1 0 0 0      
 
    1 E Total Registrations   5 1 1 0 0 0 08/13/2020    
            5 1 1 0 0 0      
 
  EA9171-CML, Anti-PD-1 Pembrolizumab + TKIs 0 E Total Registrations   4 2 1 0 0 0 02/18/2020 78 38
            4 2 1 0 0 0      
 
    1 E Total Registrations   4 2 1 0 0 0 02/18/2020    
            4 2 1 0 0 0      
 
    2 E Total Registrations   1 0 0 0 0 0 02/18/2020    
            1 0 0 0 0 0      
 
  EA9181-ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 0 E Total Registrations   39 6 4 2 0 0 02/19/2021 165 59
            39 6 4 2 0 0      
 
    1 E Total Registrations   33 7 3 2 0 0 02/19/2021    
            33 7 3 2 0 0      
 
    2 E Total Registrations   29 6 2 1 1 0 02/19/2021    
            29 6 2 1 1 0      
 

25-MAY-2024 6:10

LEUK Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs
# of
CURR
IRBs
EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 3 Randomization 14-Oct-20 165 59
MM1YA-S01 AML, High Risk, Age <60, 7+3 vs experimental 1 Randomization 16-May-24    
MYELOMATCH MSRP for the NCI myeloMATCH Clinical Trials 1 Screening 16-May-24    
  2 Re-screening 16-May-24    
  3 Re-screening 16-May-24    
  4 Re-screening 16-May-24